132 related articles for article (PubMed ID: 11440899)
1. GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve.
Brandt A; Katschinski M; Arnold R; Polonsky KS; Göke B; Byrne MM
Am J Physiol Endocrinol Metab; 2001 Aug; 281(2):E242-7. PubMed ID: 11440899
[TBL] [Abstract][Full Text] [Related]
2. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
Kjems LL; Holst JJ; Vølund A; Madsbad S
Diabetes; 2003 Feb; 52(2):380-6. PubMed ID: 12540611
[TBL] [Abstract][Full Text] [Related]
3. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
[TBL] [Abstract][Full Text] [Related]
4. Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.
Ahrén B; Holst JJ; Mari A
Diabetes Care; 2003 Oct; 26(10):2860-4. PubMed ID: 14514592
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
7. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
Egan JM; Meneilly GS; Habener JF; Elahi D
J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
[TBL] [Abstract][Full Text] [Related]
10. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region.
Dardevet D; Moore MC; Neal D; DiCostanzo CA; Snead W; Cherrington AD
Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E75-81. PubMed ID: 15026303
[TBL] [Abstract][Full Text] [Related]
11. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
[TBL] [Abstract][Full Text] [Related]
12. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
Toft-Nielsen MB; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2001 Aug; 86(8):3853-60. PubMed ID: 11502823
[TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
Byrne MM; Gliem K; Wank U; Arnold R; Katschinski M; Polonsky KS; Göke B
Diabetes; 1998 Aug; 47(8):1259-65. PubMed ID: 9703326
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.
Juhl CB; Schmitz O; Pincus S; Holst JJ; Veldhuis J; Pørksen N
Diabetologia; 2000 May; 43(5):583-8. PubMed ID: 10855533
[TBL] [Abstract][Full Text] [Related]
15. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
Toft-Nielson M; Madsbad S; Holst JJ
Diabetes; 1996 May; 45(5):552-6. PubMed ID: 8621002
[TBL] [Abstract][Full Text] [Related]
16. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
[TBL] [Abstract][Full Text] [Related]
17. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
18. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
[TBL] [Abstract][Full Text] [Related]
19. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
Fritsche A; Stefan N; Hardt E; Schützenauer S; Häring H; Stumvoll M
Eur J Clin Invest; 2000 May; 30(5):411-8. PubMed ID: 10809901
[TBL] [Abstract][Full Text] [Related]
20. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
